Quell Therapeutics: QC Labs
16 May 2024
9 Months
Guys & St Thomas Hospital, London
Quell was founded in March 2019 in partnership with six prominent immunological experts from King’s College London, University College London and Hannover Medical School, and is led by Iain McGill, a leading pharmaceutical executive with extensive relevant experience, having spent the majority of his 25 years in the industry in immunology, including the areas of solid organ and cell transplantation. The Company was founded with initial series A financing, led by Syncona Ltd who committed £34M with a further £1M contributed by UCL Technology Fund.
The Project
EEDN were engaged to deliver an Operational QC lab on the tenth floor of the Cell & Gene Therapy Catapult (GCTC) unit at Guys & St Thomas Hospital (GSTT) at London Bridge. Our role included the Project Management of the Fit Out and Operational Readiness elements of the project.
Our role
Our Director, Tes Adamou led the day-to-day Project Management of the facility, including:
- Purchasing, installation and qualification activities of all existing and new equipment
- Method transfers to new QC laboratory
- Preparation of necessary documentation (e.g. SOPs)
- Commissioning, Qualification and Validation process
Challenges
The project involved a number of stakeholders, including internal stakeholders of the client as well as stakeholders from CGTC and GSTT and had to align with the timelines and constraints of developing a project in a live hospital and research environment.
We integrated a collaborative approach and prioritisation methodology based on knowledge of the industry, equipment procurement timelines and a full CQV process for the equipment and facility.
